0
0
Lucknow’s Central Drug Research Institute (CDRI) has made a significant stride in orthopedic medicine with the development of an oral pill poised to revolutionize fracture healing.
Dubbed CDRI-1500, the molecule is set to undergo phase-1 clinical trials shortly, marking a crucial step towards its potential availability for patients in need.
Senior principal scientist at CDRI, Divya Singh, emphasized the pressing need for such innovations in India, given the country’s high accident rate leading to substantial morbidity and mortality. She noted, “As accidents remain a significant concern, the development of a medication that offers rapid relief, devoid of side effects, and accelerates fracture healing is paramount.”
Singh revealed that CDRI is concurrently investigating another bone healing entity, CDRI-399, in addition to CDRI-1500. With all necessary approvals secured from regulatory bodies, CDRI is poised to initiate the phase-1 clinical trial for CDRI-1500 imminently.
Describing CDRI-1500 as a groundbreaking orally active fracture healing synthetic molecule, Singh highlighted its unique status as the first of its kind nationally and internationally. While the FDA has approved the use of the BMP2 molecule for fractures, its usage is curtailed due to associated clinical complications and high costs.
In contrast, CDRI-1500 promises both safety and cost-effectiveness, offering expedited pain relief by promoting the expression of genes crucial for bone regeneration and repair.
Singh emphasized the pill’s remarkable efficacy, even at low doses, noting its success in promoting fracture healing in laboratory animals like Sprague Dawley rats and New Zealand white rabbits. The molecule’s potential has garnered recognition, securing patents both in India and the United States.
The development of CDRI-1500 represents a breakthrough in orthopedic medicine, poised to address a critical need for safer, more accessible fracture healing solutions. As clinical trials progress, CDRI’s innovation offers hope for millions grappling with fractures, promising a future where recovery is expedited, and complications minimized.
